Buy
Average UserBuy
Average AnalystSlightly Bearish
Stock Target AdvisorUSD 224.91
-1.49 (-0.66)%
USD 27.73B
0.75M
USD 232.48(+3.37%)
Buy
Average UserBuy
Average AnalystSlightly Bearish
Stock Target AdvisorUSD 27.73B
USD 224.91
Based on the Alnylam Pharmaceuticals Inc stock forecasts from 18 analysts, the average analyst target price for Alnylam Pharmaceuticals Inc is USD 232.48 over the next 12 months. Alnylam Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Alnylam Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Alnylam Pharmaceuticals Inc’s stock price was USD 224.91. Alnylam Pharmaceuticals Inc’s stock price has changed by -1.79% over the past week, -5.36% over the past month and +55.19% over the last year.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metaboli...Read More
675 West Kendall Street, Cambridge, MA, United States, 02142
1,665
December
USD
USA
0.50
USD 242.97
8.10
USD 117.58
5,679,258
USD 187.48
5,112,936
USD 227.22
0.54%
5.42%
100.91%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
|
Vertex Pharmaceuticals Inc | -5.83 (-1.80%) | USD82.14B | 25.24 | 16.84 |
|
Regeneron Pharmaceuticals Inc | -0.47 (-0.06%) | USD80.20B | 15.52 | 12.07 |
|
Moderna Inc | -1.76 (-1.00%) | USD67.64B | 6.64 | 5.34 |
|
Alexion Pharmaceuticals Inc | 0.00 (0.00%) | USD40.34B | 59.23 | 42.56 |
|
BioNTech SE | -0.36 (-0.25%) | USD34.86B | 3.27 | 2.14 |
|
BeiGene Ltd | -1.72 (-0.67%) | USD26.95B | N/A | -9.58 |
|
Seagen Inc | -0.45 (-0.32%) | USD25.90B | 55.02 | -38.86 |
|
Genmab AS | -0.03 (-0.08%) | USD25.68B | 30.85 | 3.59 |
|
Biomarin Pharmaceutical Inc | +1.36 (+1.18%) | USD21.32B | 266.74 | 90.91 |
|
argenx NV ADR | -2.52 (-0.66%) | USD21.13B | N/A | -21.25 |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
|
Direxion mRNA ETF | 6.57 % | 0.65 % | +0.18 (+1.16%) | USD4.43M |
|
ETFMG Treatments Testing .. | 6.06 % | 0.68 % | -0.10 (-0.40%) | USD0.02B |
|
Global X Genomics & Biote.. | 4.28 % | 0.50 % | +0.22 (+1.62%) | USD0.23B |
|
Vesper U.S. Large Cap Sho.. | 4.02 % | 0.75 % | +0.02 (+0.08%) | USD0.07B |
|
L&G Pharma Breakthrough U.. | 3.25 % | 0.00 % | -0.06 (-0.54%) | N/A |
|
L&G Pharma Breakthrough U.. | 3.25 % | 0.49 % | -0.10 (-0.93%) | USD0.04B |
|
Legal & General UCITS ETF.. | 3.25 % | 0.49 % | -0.11 (-0.95%) | USD0.04B |
|
Principal Healthcare Inno.. | 3.17 % | 0.42 % | +0.35 (+0.96%) | USD0.06B |
|
VictoryShares Nasdaq Next.. | 3.15 % | 0.18 % | +0.68 (+2.61%) | USD0.10B |
|
Invesco Nasdaq Biotechnol.. | 2.59 % | 0.19 % | -0.01 (-0.05%) | USD0.02B |
|
iShares Biotechnology ETF | 2.58 % | 0.44 % | +0.16 (+0.12%) | USD8.94B |
|
iShares Nasdaq US Biotech.. | 2.56 % | 0.35 % | -0.05 (-1.03%) | USD0.47B |
|
iShares Nasdaq US Biotech.. | 2.56 % | 0.35 % | -0.07 (-1.10%) | USD0.04B |
|
iShares Nasdaq US Biotech.. | 2.56 % | 0.35 % | -0.07 (-1.14%) | USD0.47B |
|
Invesco NASDAQ Next Gen 1.. | 1.97 % | 0.15 % | +0.53 (+2.02%) | USD0.81B |
|
Motley Fool Next Index ET.. | 1.81 % | 0.50 % | +0.20 (+1.30%) | USD0.03B |
|
Nationwide Risk-Based U.S.. | 0.71 % | 0.30 % | 0.00 (0.00%) | USD0.11B |
|
Etho Climate Leadership U.. | 0.57 % | 0.47 % | +0.99 (+1.84%) | USD0.18B |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.